2018年临床癌症进展:美国临床肿瘤学会抗癌进展年度报告
该报告由美国临床肿瘤学会(ASCO)发布,2018年年度进展为过继性细胞免疫治疗,其中嵌合抗原受体(CAR)T细胞疗法在儿童急性淋巴细胞白血病、成人淋巴瘤和多发性骨髓瘤中取得显著结果。报告同时强调联邦科研资助对推动此类突破及精准医学可及性的重要性。
要点
- 2018年ASCO年度进展为过继性细胞免疫治疗。
- CAR T细胞疗法在儿童急性淋巴细胞白血病、成人淋巴瘤和多发性骨髓瘤中取得显著结果。
- 报告强调持续的联邦科研投入对推动癌症治疗创新至关重要。
核心结论
- 2018年ASCO年度进展为过继性细胞免疫治疗,CAR T细胞疗法在儿童急性淋巴细胞白血病、成人淋巴瘤和多发性骨髓瘤中取得显著结果。
研究设计与样本
- 美国临床肿瘤学会(ASCO)发布的年度报告,由ASCO主席撰写致辞并汇总年度进展。
主要发现
- 过继性细胞免疫治疗可基因重编程患者自身免疫细胞以寻找并攻击全身癌细胞。
- CAR T细胞疗法在儿童急性淋巴细胞白血病、成人淋巴瘤和多发性骨髓瘤中取得显著结果。
- 儿童急性淋巴细胞白血病首个CAR T细胞疗法临床试验部分由美国国家癌症研究所(NCI)资助。
- NCI癌症研究中心的研究者首次报告CAR T细胞疗法用于多发性骨髓瘤的可能性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A MESSAGE FROM ASCO'S PRESIDENT I remember when ASCO first conceived of publishing an annual report on the most transformative research occurring in cancer care. Thirteen reports later, the progress we have chronicled is remarkable, and this year is no different. The research featured in ASCO's Clinical Cancer Advances 2018 report underscores the impressive gains in our understanding of cancer and in our ability to tailor treatments to tumors' genetic makeup. The ASCO 2018 Advance of the Year, adoptive cell immunotherapy, allows clinicians to genetically reprogram patients' own immune cells to find and attack cancer cells throughout the body. Chimeric antigen receptor (CAR) T-cell therapy-a type of adoptive cell immunotherapy-has led to remarkable results in young patients with acute lymphoblastic leukemia (ALL) and in adults with lymphoma and multiple myeloma. Researchers are also exploring this approach in other types of cancer. This advance would not be possible without robust federal investment in cancer research. The first clinical trial of CAR T-cell therapy in children with ALL was funded, in part, by grants from the National Cancer Institute (NCI), and researchers at the NCI Center for Cancer Research were the first to report on possible CAR T-cell therapy for multiple myeloma. These discoveries follow decades of prior research on immunology and cancer biology, much of which was supported by federal dollars. In fact, many advances that are highlighted in the 2018 Clinical Cancer Advances report were made possible thanks to our nation's support for biomedical research. Funding from the US National Institutes of Health and the NCI helps researchers pursue critical patient care questions and addresses vital, unmet needs that private industry has little incentive to take on. Federally supported cancer research generates the biomedical innovations that fuel the development and availability of new and improved treatments for patients. We need sustained federal research investment to accelerate the discovery of the next generation of cancer treatments. Another major trend in this year's report is progress in precision medicine approaches to treat cancer. Although precision medicine offers promise to people with cancer and their families, that promise is only as good as our ability to make these treatments available to all patients. My presidential theme, "Delivering Discoveries: Expanding the Reach of Precision Medicine," focuses on tackling this formidable challenge so that new targeted therapies are accessible to anyone who faces a cancer diagnosis. By improving access to high-quality care, harnessing big data on patient outcomes from across the globe, and pursuing innovative clinical trials, I am optimistic that we will speed the delivery of these most promising treatments to more patients. Sincerely, Bruce E. Johnson, FASCO ASCO President, 2017 to 2018.
引用
- Heymach J, Krilov L, Alberg A, et al. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2018. PMID: 29380678. doi:10.1200/JCO.2017.77.0446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。